Brandon Sim, Co-Chief Executive Officer of ApolloMed, stated, "We are excited about integrating Orma Health's business and technological capabilities with those of ApolloMed, tapping their leadership team's experience in working with DCEs and helping risk-bearing provider groups in the delivery of value-based care as we augment our capabilities to support providers in various Centers for Medicare & Medicaid Services Innovation Models. We believe this acquisition will further differentiate ApolloMed's technology platform and analytic capabilities while adding complementary lines of business to our operations that serve as business development opportunities."
Through leveraging its proprietary technology platform and extensive value-based care experience, ApolloMed has historically demonstrated tremendous success participating in Centers for Medicare & Medicaid Services ("CMS") Innovation Models. The acquisition of Orma Health serves to accelerate ApolloMed's product roadmap in developing an end-to-end technology platform that enables providers to succeed in all CMS Innovation Models, including DCE. Orma Health's real-time Clinical AI and RPM technologies will also be integrated into ApolloMed's existing solutions for its managed care populations and will further enhance ApolloMed's technology and analytics offering to its 1.2 million Medicare Advantage, Managed Medicaid, Commercial, and ACA members nationwide. This will allow ApolloMed providers to receive an additional layer of real-time, actionable insights and continue delivering high-quality care to their patients, tailored to their membership populations. As ApolloMed looks to expand its membership and enter new geographies, there are significant business development opportunities in deepening Orma Health's relationships with existing RPM providers and patients and extending that to ApolloMed's managed care and CMS Innovation Model solutions and offerings.
Dans le cadre de l'acquisition, Neil Ahuja, co-fondateur et chef de la direction d'Orma Health, se joindra à Apollomed en tant que président, Solutions de fournisseur et fermer les efforts continus pour permettre aux médecins de passer avec succès à des modèles de soins fondés sur une valeur.Yubin Park, co-fondateur et directeur de la technologie d'Orma Health, se joindra à Apollomed en tant que directeur de l'analyse et dirigera le développement et l'intégration continus de la technologie d'activation des fournisseurs AI-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-Drived sur la plate-forme technologique d'ApollomEd.
M. Ahuja a déclaré: «Nous sommes ravis de rejoindre ApollomEd, apportant les compétences de base d'Orma Health dans le développement de technologies de soins de santé innovantes qui stimulent les résultats tangibles pour les prestataires et leurs patients.Rendre les médecins dans la prestation de soins fondés sur la valeur, ce qui en fait le partenaire parfait pour nous. Nous sommes impatients de contribuer à notre expertise à l'élargissement des capacités MSO d'ApollomEd et aux opportunités futures potentielles qui nous attendent. "
M. Park a ajouté: "Je suis ravi de commencer à travailler en étroite collaboration avec l'équipe Apollomed pour intégrer les technologies d'Orma Health avec celle de l'apollomé. Chez Orma Health, nous, comme apollomé, croyons que les données sont le roi. Les informations que nous collectons et analysons sur notreAu fil des ans, les membres sont essentiels à notre capacité à offrir la meilleure expérience de santé et les résultats pour les patients. Nous sommes ravis qu'Orma Health fasse désormais partie de la digne mission d'ApollomEd d'autonomisation des prestataires de prestation de soins de haute qualité et de résultats améliorés pour ses membres."
Selon les termes de l'accord, une partie du prix d'achat a été payée en espèces aux détenteurs de capitaux propres d'Orma Health à la clôture de la transaction, une autre partie a été payée en actions apollomées aux détenteurs d'actions d'Orma Health à la fermeture de la fermeture deLa transaction et le reste du prix d'achat doivent être payés dans une combinaison de trésorerie et d'actions aux détenteurs de capitaux propres en fonction d'Orma Health atteignant certaines étapes opérationnelles au cours des 18 mois après la clôture.La Société financera la transaction en espèces en espèces et actions des actions Apollomed.
About Apollo Medical Holdings, Inc.ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.
Basée à l'Alhambra, en Californie, les filiales et les sociétés affiliées d'Apollomed comprennent les organisations de services de gestion (MSOS), les associations de pratiques indépendantes (IPA) et une organisation de soins responsables de nouvelle génération (NGACO).Pour plus d'informations, veuillez visiter www.apollomed.net.
Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements included in this press release that are not a description of historical facts are forward-looking statements. Words and phrases such as "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "seek," "plan," "expect," "should," "would" or similar expressions are intended to identify forward-looking statements and are based on the Company's current beliefs and expectations. These forward-looking statements include, without limitation, statements about the Company's acquisition of and arrangements with Orma Health, integration of Orma Health into ApolloMed operations, benefits and synergies of the transaction, future opportunities for the combined businesses, ApolloMed's ability to deliver sustainable long-term value, ability to respond to the changing environment, operational focus, strategic growth and expansion plans, and future collaboration opportunities, and any other statements regarding events or developments that the Company believes or anticipates will or may occur in the future. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of ApolloMed's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in ApolloMed's reports filed with the Securities and Exchange Commission, including, without limitation, the risk factors contained in ApolloMed's Annual Report on Form 10-K for the year ended December 31, 2020, and any subsequent Quarterly Reports on Form 10-Q.
FOR MORE INFORMATION, PLEASE CONTACT:Investor Relations(626) 943-6491[email protected]
Carolyne Sohn, The Equity Group (415) 568-2255 [Protégé par e-mail]
Source Apollo Medical Holdings, Inc.
